SBIR/STTR Panel Moderator
Anna Lisa is an experienced medical device consultant, venture capitalist, intellectual property analyst, technology transfer specialist, biomedical researcher, and entrepreneur specialized in early-stage, cutting edge technology businesses. She has been a part of the entrepreneurial community for 14 years. She helped drive the formation and raised angel and venture funding for several start-up companies while also serving as top management for many of the ventures. She co-founded and was a Director for OrthoAccel Technologies, Inc., a medical device company that received 510k clearance and CE marking for its orthodontic device whose products are sold globally. She currently leads regulatory and quality efforts at Briteseed, LLC and American BioOptics, Inc. She also has extensive experience in non-dilutive funding having helped new technology ventures receive over $20M in SBIR/STTR, state and private grants. She is a grant consultant to the University of Chicago, Illinois University Incubator Network, and Argonne National Laboratory.
I have leaded teams working on applying machine learning in different areas, such as bioinformatics, social media marketing, property insurance and legal. I'm very interested in the opportunities in bio-pharma, such as imaging diagnosis and precision medicine. I'd love to be part of the conversation on your great conference platform.
Dr. Han Dai is currently a Scientific Leader and GSK Fellow in Future Pipeline Discovery at GlaxoSmithKline and a GSK Visiting Professor at High Magnetic Field Laboratory (HMFL), Chinese Academy of Sciences (CAS). He has been working in the pharmaceutical industries for ~10 years, starting with responsibilities in protein chemistry, enzymology, biophysics & structural biology and expanding quickly into preclinical drug discovery program management and leadership, managing also cell biology, DMPK, and pharmacology aspects of programs. He has broad understanding of the discovery value chain from target validation to pre-clinical development and experiences in project leadership, managing collaboration of multidisciplinary matrix research teams within company and with external CROs, non-profit academic collaborators and risk-sharing partners. He has won a number of awards at GSK including several GSK Exceptional Science Awards and the most recent GSK Recognition Award for multiple Clinical Candidate Selections. He has published more than 40 papers, book chapter, abstracts and patents in reputable journals (including Nature Communications, Nature Structural and Molecular Biology, Science, Cell), and conferences, serving as the first and corresponding author, a frequently invited journal reviewer, an editorial board member for several journals, and an invited speaker at international conferences. Han is actively involved in community services, including GSK Alternative Discovery & Development Communications and Engagement, GSK R&D Data Science Matrix Group, LRIG Philadelphia Steering Committee, the Adhesion GPCR Consortium as an Associate Member and F1000 Drug Discovery & Design Section as a Full Faculty Member. Han also serves as previously the Vice President of Business Development and currently the President-Elect of Sino-American Pharmaceutical Professional Association ¨C Greater Philadelphia (SAPA-GP) and an Executive Council member of Sino-American Pharmaceutical Professional Association (SAPA). Han completed his Bachelor of Science in Department for Intensive Instructions at Nanjing University in Nanjing, China, his Ph.D. at UT Southwestern Medical Center at Dallas as a Frank and Sara McKnight fellow, his postdoctoral training in Harvard Medical School as a Helen Hay Whitney fellow.
Associate Professor at the University of Virginia. Founder of OncoTargeting LLC. Oncogene discovery.
Consultant for Prosit Sole Biotechnology and CEO of Orphanon Inc.
The main purpose to attend this meeting is to expand network
Cathay Bank is a public trade bank which is established in 1962, We are a full services bank and currently operating 65 branches in 9 states with one oversea branch in Hong Kong, representative offices in Taipei & Shanghai.
NIH SBIR/STTR Panel participant
WARF is the designated patent and licensing organization for UW-Madison. Founded in 1925, WARF is among the oldest and most successful technology transfer offices in the nation.
Hello Dr. Zhu I found your office abandoned the other week. I guess you have moved on from Abbvie. My congratulations my brother - but why am I always the last to know? I have two colleagues from Teledyne ISCO interested in joining me in at the Yao Yuan at the end of this month. Could I ask you to create badges for them as well? Michael Sushan & Michael Xie are both Teledyne ISCO employees representing our syringe pump & Chromatography products. What are the hours of the exposition? What is a good time to set up on Thursday & break down on Friday? Best Steve Paeschke 773-562-3882, firstname.lastname@example.org
I am a faculty member at UW-Madison. I have been in the medicinal chemistry division of the School of Pharmacy for over ten years. My research program focuses on small molecule drug discovery.
My research focuses on developing clinically relevant and molecularly profiled patient-derived xenograft (PDX) tumor models that aid in understanding cancerous genetic abnormalities, identifying predictive biomarkers for diagnosis and treatment of cancer, and most importantly, developing personalized medicine strategies.
YINGMING ZHAO, PHD
Professor, Ben May Department for Cancer Research, The University of Chicago
Yingming’s main research interests lie in developing and applying MS-based proteomics technologies to discovery of undescribed cellular pathways (with current focus on protein post-translational modification (PTM) pathways and epigenetic mechanism) and identification of biomarkers for precision medicine. He uses an integrated approach, involving proteomics, biochemistry, molecular biology, and cell biology to decode PTM networks that have implications for human health and are not amenable to conventional techniques. His lab recently discovered nine types of new lysine acylation pathways: propionylation, butyrylation, crotonylation, malonylation, succinylation, glutarylation, and 2-hydroxyisobutyrylation, 3-hydroxybutyrylation, benzoylation. They identified about 500 new histone marks, which more than doubles the number of previously described histone marks that were discovered over the past few decades. They identified and characterized protein substrates, specific binders and regulatory enzymes for the new PTM pathways. His laboratory demonstrates that the new PTM pathways have critical roles in epigenetic regulation and cellular metabolism. And these pathways contribute to physiology changes and cellular dysfunctions associated with diverse inborn metabolic diseases, therefore offering new avenues for therapeutic intervention. Yingming also uses the proteomics technology for identifying proteomic signatures, proteins and protein PTMs (including histone marks), that can classify tumors and predicting drug sensitivity. He is a co-inventor of numerous patents and co-authored 175 peer reviewed papers (H-Index: 80).
Yingming Zhao received his Ph.D. degree from the Rockefeller University under Professor Brian Chait in 1997. He is a co-founder and scientific advisor for multiple biotechnology and pharmaceutical companies.
Yuan-Hua Ding, PhD
Executive Director and Head of
External Science & Innovation (ES&I) – Asia/Pacific
Dr. Yuan-Hua Ding is an Executive Director and Head of Pfizer External Science and Innovation (ES&I) – Asia/Pacific, Pfizer Worldwide Research & Development (WRD). He is also a member of the ES&I leadership team. In this capacity, he partners with colleagues in ES&I, Pfizer Business Development Group and Pfizer Asia Country Offices to evaluate technologies and assets from Asia Pacific academic, biotech & pharma laboratories, seek opportunities to incubate early biotech companies, build and manage a research network of academic institutes, biotech & pharma companies, and venture capital groups as well as regional bioparks. He liaises with therapeutic area and technology research unit leaderships in accessing the sciences, technologies and products needed to support Pfizer R&D mission.
Prior to his current job, Dr. Ding served a variety of roles in the Pfizer R&D division, including Head of Asia External Science and Technology, Head of Structural Biology at the RTC Research Technology Center (RTC) in Cambridge, MA, Associate Research Fellow and Senior Research Scientist. As the Head of the RTC Structural Biology, he oversaw a group of scientists responsible for protein production, characterization, crystallization, crystallography and structure-based drug design. His group supported structural based drug design portfolio of 10+ programs, through collaborative efforts with RTC, Pfizer global structural biology groups and therapeutic area project teams, covering oncology, diabetes, inflammation and CNS. He also served as project leaders for several drug discovery programs.
Dr. Ding received a bachelor’s degree in Electronic Engineering from Peking University in 1987 and a master’s degree in Biophysics from Tsinghua University in 1990. In 1996, after completed his doctoral studies in Biochemistry with Prof. John Rosenberg and Roger Hendrix at the University of Pittsburgh, he moved to Harvard University to be a postdoctoral fellow with Prof. Don Wiley. Dr. Ding’s postdoctoral work focused on structural and biophysical aspects of molecular interactions among T-cell receptor (TCR), major histocompatibility complex (TCR) and peptide antigens. While in Dr. Wiley’s Lab, Dr Ding also collaborated with Dr. Judah Folkman of Boston Children’s Hospital on structural studies of endostatin, a protein shown to be a potent angiogenesis inhibitor in mouse model.
Yulia Komarova, PhD is an Associate Professor of Pharmacology at the University of Illinois at Chicago. Her research focuses on the signaling mechanisms regulating the endothelial barrier function in health and disease. The overarching goal of her research is to develop highly effective drug-based therapy for the treatment of vascular leakage and accompanying inflammation in the lung of patients with Acute Respiratory Distress Syndrome and ocular diseases. Dr. Komarova is a lead inventor on 3 international patents.
I am a life sciences lawyer at Sidley Austin LLP's DC office, servicing as a member of our firm's top-ranking FDA regulatory practice group. I am also a member of our firm's China Life Sciences practice. We have helped a lot of innovative biotech companies navigate through the complex regulatory landscape in both US and China. I wish to join this conference to introduce our firm to more stakeholders in the life sciences industry and also learn the current market trend. Thank you.